Abstract
Background: Traumatic brain injury (TBI) is the leading cause of death and disability among children and young adults worldwide. The 5-HT2C and melatonin receptors are known to have involvement in memory functions.
Objective: To find the beneficial effect of agomelatine against weight drop induced TBI in rats.
Method: The weight-drop model closely mimics the real-life TBI. The injury was induced by dropping a weight of 450 gm from a height of 1 meter through a hollow metallic tube onto the exposed skull of rats under anesthesia. After 14 days of TBI, the agomelatine (10, 20, and 40 mg/kg p.o. daily) treatment was given for next 14 days (i.e. until 28th day). The cognitive impairment was observed in Morris water maze (from 24th to 28th day) and novel object recognition (on 27th and 28th day) test. Immediately after behavioral parameters, animals were sacrificed and hippocampus and cortex were isolated for biochemical, neuroinflammatory and neurochemical estimation.
Results: The weight drop model significantly induced memory impairment in TBI rats that has been assessed by Morris water maze and object recognition task. A significant rise in acetylcholinesterase activity, neuroinflammatory markers, oxidative stress was found in both cortex and hippocampal regions of traumatized rat brain. While agomelatine (10, 20, and 40 mg/kg p.o.) treated rats have shown memory enhancing effects dose-dependently, as compared to TBI control rats in Morris water maze as well as novel object recognition test. Further, agomelatine treated rats have shown a significant increase in serotonin, dopamine and norepinephrine levels in TBI rat brain.
Conclusion: Agomelatine treated rats have been shown to alter the cognitive deficit due to TBI by enhancing the memory as shown in Morris water maze and object recognition test, as well as a substantial rise in neurotransmitters, suggesting that agomelatine may possess memory-enhancing effects. Hence, we deduce that agomelatine may represent a promising new neuroprotective drug for cognitive enhancing effects in TBI.
Keywords: Traumatic Brain Injury, agomelatine, 5-HT2C, weight drop model, cognitive deficit, neurotransmitters.
Graphical Abstract
Current Psychopharmacology
Title:Protective Effect of Agomelatine on Traumatic Brain Injury Induced Cognitive Deficit in Rats: Possible Role of Neurotransmitters
Volume: 7
Author(s): Tavleen Kaur, Puneet Kumar*Sumit Jamwal
Affiliation:
- Pharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga-142001, Punjab,India
Keywords: Traumatic Brain Injury, agomelatine, 5-HT2C, weight drop model, cognitive deficit, neurotransmitters.
Abstract: Background: Traumatic brain injury (TBI) is the leading cause of death and disability among children and young adults worldwide. The 5-HT2C and melatonin receptors are known to have involvement in memory functions.
Objective: To find the beneficial effect of agomelatine against weight drop induced TBI in rats.
Method: The weight-drop model closely mimics the real-life TBI. The injury was induced by dropping a weight of 450 gm from a height of 1 meter through a hollow metallic tube onto the exposed skull of rats under anesthesia. After 14 days of TBI, the agomelatine (10, 20, and 40 mg/kg p.o. daily) treatment was given for next 14 days (i.e. until 28th day). The cognitive impairment was observed in Morris water maze (from 24th to 28th day) and novel object recognition (on 27th and 28th day) test. Immediately after behavioral parameters, animals were sacrificed and hippocampus and cortex were isolated for biochemical, neuroinflammatory and neurochemical estimation.
Results: The weight drop model significantly induced memory impairment in TBI rats that has been assessed by Morris water maze and object recognition task. A significant rise in acetylcholinesterase activity, neuroinflammatory markers, oxidative stress was found in both cortex and hippocampal regions of traumatized rat brain. While agomelatine (10, 20, and 40 mg/kg p.o.) treated rats have shown memory enhancing effects dose-dependently, as compared to TBI control rats in Morris water maze as well as novel object recognition test. Further, agomelatine treated rats have shown a significant increase in serotonin, dopamine and norepinephrine levels in TBI rat brain.
Conclusion: Agomelatine treated rats have been shown to alter the cognitive deficit due to TBI by enhancing the memory as shown in Morris water maze and object recognition test, as well as a substantial rise in neurotransmitters, suggesting that agomelatine may possess memory-enhancing effects. Hence, we deduce that agomelatine may represent a promising new neuroprotective drug for cognitive enhancing effects in TBI.
Export Options
About this article
Cite this article as:
Kaur Tavleen , Kumar Puneet *, Jamwal Sumit , Protective Effect of Agomelatine on Traumatic Brain Injury Induced Cognitive Deficit in Rats: Possible Role of Neurotransmitters, Current Psychopharmacology 2018; 7 (2) . https://dx.doi.org/10.2174/2211556007666180601100641
DOI https://dx.doi.org/10.2174/2211556007666180601100641 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Electronic Fetal Heart Rate Monitoring: The Future
Current Women`s Health Reviews Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets The Clinical Neuroscience of Post Stroke Depression
Current Neuropharmacology Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research The Quest to Repair the Damaged Spinal Cord
Recent Patents on CNS Drug Discovery (Discontinued) The Potential Applications of Stem Cells for Cancer Treatment
Current Stem Cell Research & Therapy Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Nanocapsulated Ascorbic Acid in Combating Cerebral Ischemia Reperfusion- Induced Oxidative Injury in Rat Brain
Current Alzheimer Research Synaptic and Extrasynaptic Glutamate Signaling in Ischemic Stroke
Current Medicinal Chemistry Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases
Current Neuropharmacology Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy